KTB Network

KTB Network, now operating as Daol Investment, is a Seoul-based venture and growth investor with a long history in Korean and broader Asian capital markets and a healthcare focus spanning biotechnology and pharmaceutical therapeutics. The firm participates in life sciences company creation, growth financings, and selective mid-market healthcare buyouts. There is no marketed artificial intelligence thesis specific to healthcare. Limited public information is available about individually named investment partners attached to specific healthcare deals or a comprehensive public portfolio at the sub-vertical level beyond the firm’s broader Daol Investment disclosures.

The firm engages at Series A, Series B, and growth stages with check sizes typically in the five to twenty-five million dollar range. Geographic concentration is South Korea and the broader Asia-Pacific region, with selective transatlantic exposure where Korean biotech assets attract international co-investors or seek US clinical development. Capital deployment reflects an institutional venture and growth posture, with multi-year holding periods aligned with biotech development cycles and pharmaceutical commercialization timelines rather than rapid venture turnover.

For founders, KTB Network or Daol Investment is most relevant when building a Korean biotech or pharmaceutical company with strong scientific foundations, defensible intellectual property, and a credible clinical or commercial development plan. Engagement typically begins through Korean academic medical centers, technology transfer offices, or co-investors familiar to the firm. Diligence is rigorous on biology, mechanism, regulatory pathway, and management capability. Founders should expect a partnership oriented toward clinical inflection points, eventual exit alignment with Asian or global pharmaceutical strategics, and structured governance consistent with one of the more established institutional venture franchises in Korea.